"Interchangeable" Biosimilars Get Same Medicare Code As Innovators In Bill
Executive Summary
Innovator biologics may be in for added pricing pressure from biosimilars under Medicare Part B payment and billing code requirements in the House health reform bill unveiled Oct. 29
You may also be interested in...
Pediatric Exclusivity For Brand Biologics Added In Senate FOB Provision, But Generics Have $1 Bil. In Leverage From CBO Score
The roll-out of the health care reform bill now under debate in the Senate is a good news/bad news event for the generic industry
Follow-On Biologics' Other Pathway: Mechanisms To Resolve Patent Disputes Vary In Legislation
The debate over follow-on biologics legislation has largely focused on the length of data exclusivity that should be awarded to innovators. But provisions for resolving patent disputes between innovators and follow-on applicants are also a source of contention
Follow-On Biologics' Other Pathway: Mechanisms To Resolve Patent Disputes Vary In Legislation
The debate over follow-on biologics legislation has largely focused on the length of data exclusivity that should be awarded to innovators. But provisions for resolving patent disputes between innovators and follow-on applicants are also a source of contention